JP6437559B2 - Ｗｅｅ−１キナーゼ阻害剤として有用なピリミドピリミジノン - Google Patents
Ｗｅｅ−１キナーゼ阻害剤として有用なピリミドピリミジノン Download PDFInfo
- Publication number
- JP6437559B2 JP6437559B2 JP2016541294A JP2016541294A JP6437559B2 JP 6437559 B2 JP6437559 B2 JP 6437559B2 JP 2016541294 A JP2016541294 A JP 2016541294A JP 2016541294 A JP2016541294 A JP 2016541294A JP 6437559 B2 JP6437559 B2 JP 6437559B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- amino
- group
- dichlorophenyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VLOJEWGCECYEAM-UHFFFAOYSA-N CC1(C=CC(Nc(nc2)nc(N(C)CN3c(c(Cl)ccc4)c4Cl)c2C3=O)=CC1)N1C(C2)CNC2C1 Chemical compound CC1(C=CC(Nc(nc2)nc(N(C)CN3c(c(Cl)ccc4)c4Cl)c2C3=O)=CC1)N1C(C2)CNC2C1 VLOJEWGCECYEAM-UHFFFAOYSA-N 0.000 description 1
- YUPAEYHVCOZVOK-MDYZWHIJSA-N CC1(C=CC(Nc(nc2N(C)CN3c(c(Cl)ccc4)c4Cl)ncc2C3=O)=CC1)N1[C@H](CO)CN(C)CC1 Chemical compound CC1(C=CC(Nc(nc2N(C)CN3c(c(Cl)ccc4)c4Cl)ncc2C3=O)=CC1)N1[C@H](CO)CN(C)CC1 YUPAEYHVCOZVOK-MDYZWHIJSA-N 0.000 description 1
- 0 CN(C(*)(*)N1c(c(Cl)ccc2)c2Cl)c(nc(Nc(cc2)ccc2N2CCNCC2)nc2)c2C1=O Chemical compound CN(C(*)(*)N1c(c(Cl)ccc2)c2Cl)c(nc(Nc(cc2)ccc2N2CCNCC2)nc2)c2C1=O 0.000 description 1
- TYNDDJWXWHJULJ-UHFFFAOYSA-N CN(CC1)CCC1Oc(cc1)ccc1Nc(nc1)nc(N(C)CN2c(c(Cl)ccc3)c3Cl)c1C2=O Chemical compound CN(CC1)CCC1Oc(cc1)ccc1Nc(nc1)nc(N(C)CN2c(c(Cl)ccc3)c3Cl)c1C2=O TYNDDJWXWHJULJ-UHFFFAOYSA-N 0.000 description 1
- HKRAKIIDROVHCU-UHFFFAOYSA-N CN(CN1c(c(Cl)ccc2)c2Cl)c(nc(Nc(cc2)ccc2N(CC2)CCS2(=O)=O)nc2)c2C1=O Chemical compound CN(CN1c(c(Cl)ccc2)c2Cl)c(nc(Nc(cc2)ccc2N(CC2)CCS2(=O)=O)nc2)c2C1=O HKRAKIIDROVHCU-UHFFFAOYSA-N 0.000 description 1
- PIUTZCHAHKDSNS-UHFFFAOYSA-N CN(CN1c(c(Cl)ccc2)c2Cl)c2nc(Nc(cc3)cc(CNCC(F)(F)F)c3N3CCNCC3)ncc2C1=O Chemical compound CN(CN1c(c(Cl)ccc2)c2Cl)c2nc(Nc(cc3)cc(CNCC(F)(F)F)c3N3CCNCC3)ncc2C1=O PIUTZCHAHKDSNS-UHFFFAOYSA-N 0.000 description 1
- ZDMVUMOTHMZRQP-UHFFFAOYSA-N CN(CN1c(c(Cl)ccc2)c2Cl)c2nc(Nc(cc3)ccc3N3CCN(CC(O)=O)CC3)ncc2C1=O Chemical compound CN(CN1c(c(Cl)ccc2)c2Cl)c2nc(Nc(cc3)ccc3N3CCN(CC(O)=O)CC3)ncc2C1=O ZDMVUMOTHMZRQP-UHFFFAOYSA-N 0.000 description 1
- LTHCLGLQFVDPSF-UHFFFAOYSA-N CN(CN1c(c(F)ccc2)c2Cl)c(nc(Nc(cc2)ccc2N2CC(COC)NCC2)nc2)c2C1=O Chemical compound CN(CN1c(c(F)ccc2)c2Cl)c(nc(Nc(cc2)ccc2N2CC(COC)NCC2)nc2)c2C1=O LTHCLGLQFVDPSF-UHFFFAOYSA-N 0.000 description 1
- SZLLSOCIXPGJLW-WMZOPIPTSA-N CN(CN1c(cccc2)c2Cl)c(nc(Nc(cc2)ccc2N2[C@@H](C3)CN[C@@H]3C2)nc2)c2C1=O Chemical compound CN(CN1c(cccc2)c2Cl)c(nc(Nc(cc2)ccc2N2[C@@H](C3)CN[C@@H]3C2)nc2)c2C1=O SZLLSOCIXPGJLW-WMZOPIPTSA-N 0.000 description 1
- QZJJZINNSZRIHM-UHFFFAOYSA-N CN1CCN(Cc(cc2)ccc2Nc(nc2)nc(N(C)CN3c(c(Cl)ccc4)c4Cl)c2C3=O)CC1 Chemical compound CN1CCN(Cc(cc2)ccc2Nc(nc2)nc(N(C)CN3c(c(Cl)ccc4)c4Cl)c2C3=O)CC1 QZJJZINNSZRIHM-UHFFFAOYSA-N 0.000 description 1
- KORCVBOCKBZMRD-MRXNPFEDSA-N C[C@H](C1)N(C)CCN1c(cc1)ccc1Nc(nc1)nc(N(C)CN2c(c(Cl)ccc3)c3Cl)c1C2=O Chemical compound C[C@H](C1)N(C)CCN1c(cc1)ccc1Nc(nc1)nc(N(C)CN2c(c(Cl)ccc3)c3Cl)c1C2=O KORCVBOCKBZMRD-MRXNPFEDSA-N 0.000 description 1
- KVQJFGGAQBGGCB-MRXNPFEDSA-N C[C@H](C1)NCCN1c(c(COC)c1)ccc1Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O Chemical compound C[C@H](C1)NCCN1c(c(COC)c1)ccc1Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O KVQJFGGAQBGGCB-MRXNPFEDSA-N 0.000 description 1
- SAVKMENYJBWNHC-CQSZACIVSA-N C[C@H](C1)NCCN1c(cc1F)ccc1Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O Chemical compound C[C@H](C1)NCCN1c(cc1F)ccc1Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O SAVKMENYJBWNHC-CQSZACIVSA-N 0.000 description 1
- ZOKGXCGRFOEAGH-CQSZACIVSA-N C[C@H](C1)NCCN1c(ccc(Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O)c1)c1F Chemical compound C[C@H](C1)NCCN1c(ccc(Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O)c1)c1F ZOKGXCGRFOEAGH-CQSZACIVSA-N 0.000 description 1
- ZSQBZADJUMJJAA-UHFFFAOYSA-N O=C(c1c(N2C3CCC2)nc(Nc(cc2)ccc2N2CCNCC2)nc1)N3c(c(Cl)ccc1)c1Cl Chemical compound O=C(c1c(N2C3CCC2)nc(Nc(cc2)ccc2N2CCNCC2)nc1)N3c(c(Cl)ccc1)c1Cl ZSQBZADJUMJJAA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322602.2A GB201322602D0 (en) | 2013-12-19 | 2013-12-19 | Pharmaceutical compounds |
| GB1322602.2 | 2013-12-19 | ||
| PCT/GB2014/053793 WO2015092431A1 (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017500335A JP2017500335A (ja) | 2017-01-05 |
| JP6437559B2 true JP6437559B2 (ja) | 2018-12-12 |
Family
ID=50071157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016541294A Active JP6437559B2 (ja) | 2013-12-19 | 2014-12-19 | Ｗｅｅ−１キナーゼ阻害剤として有用なピリミドピリミジノン |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9850247B2 (enExample) |
| EP (1) | EP3083625B1 (enExample) |
| JP (1) | JP6437559B2 (enExample) |
| KR (1) | KR102405462B1 (enExample) |
| CN (1) | CN105829315B (enExample) |
| AU (1) | AU2014369457B2 (enExample) |
| BR (1) | BR112016014151B1 (enExample) |
| CA (1) | CA2933755C (enExample) |
| CY (1) | CY1120035T1 (enExample) |
| DK (1) | DK3083625T3 (enExample) |
| ES (1) | ES2650013T3 (enExample) |
| GB (1) | GB201322602D0 (enExample) |
| HR (1) | HRP20180080T1 (enExample) |
| HU (1) | HUE037908T2 (enExample) |
| IL (1) | IL245672B (enExample) |
| LT (1) | LT3083625T (enExample) |
| MX (1) | MX371108B (enExample) |
| NO (1) | NO3083625T3 (enExample) |
| NZ (1) | NZ720178A (enExample) |
| PL (1) | PL3083625T3 (enExample) |
| PT (1) | PT3083625T (enExample) |
| RS (1) | RS56731B1 (enExample) |
| RU (1) | RU2691105C1 (enExample) |
| SG (1) | SG11201603814TA (enExample) |
| SI (1) | SI3083625T1 (enExample) |
| SM (1) | SMT201800020T1 (enExample) |
| WO (1) | WO2015092431A1 (enExample) |
| ZA (1) | ZA201603337B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108137593B (zh) * | 2015-04-21 | 2021-01-05 | 上海交通大学医学院附属瑞金医院 | 蛋白激酶抑制剂的制备和用途 |
| EP3368538B1 (en) * | 2015-11-01 | 2021-09-01 | The Regents of The University of Colorado, A Body Corporate | Wee 1 kinase inhibitors and methods of making and using the same |
| CN109906227B (zh) * | 2016-11-16 | 2022-03-11 | 上海瑛派药业有限公司 | 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物 |
| EP3564232B1 (en) | 2016-12-27 | 2022-01-26 | Riken | Bmp-signal-inhibiting compound |
| JP6717457B2 (ja) | 2017-01-23 | 2020-07-01 | シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド | Ｗｅｅ１阻害剤としての１，２−ジヒドロ−３Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−３−オン誘導体 |
| GB201703881D0 (en) | 2017-03-10 | 2017-04-26 | Almac Discovery Ltd | Pharmaceutical compounds |
| AU2018243667A1 (en) | 2017-03-31 | 2019-10-17 | Seagen Inc. | Combinations of Chk1- and Wee1 - inhibitors |
| WO2019011228A1 (zh) * | 2017-07-10 | 2019-01-17 | 上海瑛派药业有限公司 | 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用 |
| CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| AU2018347307A1 (en) | 2017-10-09 | 2020-04-23 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| EP3694861A4 (en) | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| SI3712150T1 (sl) | 2017-11-01 | 2024-09-30 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Makrociklična spojina, ki deluje kot zaviralec WEE1 in njene uporabe |
| AU2019227823B2 (en) * | 2018-02-28 | 2024-12-12 | The Regents Of The University Of Colorado, A Body Corporate | WEE1 kinase inhibitors and methods of treating cancer using the same |
| WO2020063788A1 (zh) * | 2018-09-27 | 2020-04-02 | 贝达药业股份有限公司 | Fgfr4抑制剂及其应用 |
| EP3875460A4 (en) | 2018-10-26 | 2022-07-20 | Wuxi Biocity Biopharmaceutics Co., Ltd. | PYRIMIDINDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF |
| AU2019413360B2 (en) | 2018-12-28 | 2025-05-22 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| JP2022528047A (ja) | 2019-03-22 | 2022-06-08 | ショウヤオ ホールディングス（ベイジン） カンパニー， リミテッド | Ｗｅｅ１阻害剤、その製造および用途 |
| WO2020210383A1 (en) * | 2019-04-09 | 2020-10-15 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| WO2020210377A1 (en) * | 2019-04-09 | 2020-10-15 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| EP3952877A4 (en) | 2019-04-09 | 2022-12-14 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| ES2984617T3 (es) | 2019-04-30 | 2024-10-30 | Wuxi Biocity Biopharmaceutics Co Ltd | Forma de cristal del compuesto inhibidor de Wee1 y su uso |
| CN112142763B (zh) * | 2019-06-28 | 2024-01-26 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| CN115698006B (zh) | 2020-06-17 | 2024-03-29 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的吡唑并[3，4-d]嘧啶-3-酮衍生物 |
| WO2022072336A1 (en) * | 2020-10-01 | 2022-04-07 | University Of Washington | Drug-like molecules and methods for the therapeutic targeting of microrna-21 |
| CA3201152A1 (en) * | 2020-12-18 | 2022-06-23 | Xiaoyang Dong | Nitrogen containing 2,3-dihydroquinazolinone compounds as nav1.8 inhibitors |
| JP2024502231A (ja) * | 2020-12-18 | 2024-01-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｎａｖ１．８電位依存性ナトリウムチャネルを阻害するためおよびＮａｖ１．８介在疾患を治療するために有用な化学化合物 |
| CA3214894A1 (en) | 2021-04-30 | 2022-11-03 | Yuli Xie | Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof |
| US12161722B2 (en) | 2021-06-25 | 2024-12-10 | Korea Research Institute Of Chemical Technology | Bifunctional heterocyclic compound having BTK degradation function via ubiquitin proteasome pathway, and use thereof |
| CN116462687B (zh) | 2022-01-18 | 2025-01-07 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
| CN116836184B (zh) * | 2022-03-25 | 2025-07-25 | 药雅科技(上海)有限公司 | Wee1激酶抑制剂的制备及其应用 |
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| CN117402162A (zh) | 2022-07-13 | 2024-01-16 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
| TW202519226A (zh) | 2023-11-08 | 2025-05-16 | 美商艾克塞里克斯公司 | 使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| EP1727819A1 (en) | 2004-03-15 | 2006-12-06 | F.Hoffmann-La Roche Ag | Novel dichloro-phenyl-pyrido¬2,3-d|pyrimidine derivatives, their manufacture and use as pharmaceutical agents |
| FR2896246B1 (fr) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. |
| PE20080695A1 (es) | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| JP5411847B2 (ja) | 2007-04-25 | 2014-02-12 | Ｍｓｄ株式会社 | Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形 |
| MX2009013728A (es) | 2007-06-15 | 2010-01-25 | Banyu Pharma Co Ltd | Derivados de bicicloanilina. |
| WO2009054332A1 (ja) * | 2007-10-23 | 2009-04-30 | Banyu Pharmaceutical Co., Ltd. | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 |
| EP2376493B1 (en) * | 2008-12-12 | 2016-10-05 | Msd K.K. | Dihydropyrimidopyrimidine derivative |
| US8575179B2 (en) | 2008-12-12 | 2013-11-05 | Msd K.K. | Dihydropyrazolopyrimidinone derivatives |
| AU2011340690C1 (en) * | 2010-12-06 | 2016-03-10 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp - PLA2 |
| AR084515A1 (es) * | 2010-12-22 | 2013-05-22 | Merz Pharma Gmbh & Co Kgaa | Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras |
| TWI532742B (zh) * | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| JP2014520855A (ja) | 2011-07-15 | 2014-08-25 | アッヴィ・インコーポレイテッド | 増殖性疾患の治療に有用な三環式キナーゼ阻害薬 |
| WO2013013031A1 (en) * | 2011-07-19 | 2013-01-24 | Abbvie Inc. | Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase |
| US9181239B2 (en) | 2011-10-20 | 2015-11-10 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| JP2015511245A (ja) | 2012-02-23 | 2015-04-16 | アッヴィ・インコーポレイテッド | ピリドピリミジノン系キナーゼ阻害薬 |
| CN102816164A (zh) * | 2012-08-31 | 2012-12-12 | 北京理工大学 | 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法 |
-
2013
- 2013-12-19 GB GBGB1322602.2A patent/GB201322602D0/en not_active Ceased
-
2014
- 2014-12-19 WO PCT/GB2014/053793 patent/WO2015092431A1/en not_active Ceased
- 2014-12-19 MX MX2016007801A patent/MX371108B/es active IP Right Grant
- 2014-12-19 SM SM20180020T patent/SMT201800020T1/it unknown
- 2014-12-19 RS RS20171338A patent/RS56731B1/sr unknown
- 2014-12-19 PL PL14815843T patent/PL3083625T3/pl unknown
- 2014-12-19 HU HUE14815843A patent/HUE037908T2/hu unknown
- 2014-12-19 AU AU2014369457A patent/AU2014369457B2/en active Active
- 2014-12-19 CN CN201480069437.9A patent/CN105829315B/zh active Active
- 2014-12-19 DK DK14815843.9T patent/DK3083625T3/en active
- 2014-12-19 PT PT148158439T patent/PT3083625T/pt unknown
- 2014-12-19 JP JP2016541294A patent/JP6437559B2/ja active Active
- 2014-12-19 SI SI201430580T patent/SI3083625T1/en unknown
- 2014-12-19 ES ES14815843.9T patent/ES2650013T3/es active Active
- 2014-12-19 EP EP14815843.9A patent/EP3083625B1/en active Active
- 2014-12-19 NZ NZ720178A patent/NZ720178A/en unknown
- 2014-12-19 US US15/105,869 patent/US9850247B2/en active Active
- 2014-12-19 SG SG11201603814TA patent/SG11201603814TA/en unknown
- 2014-12-19 HR HRP20180080TT patent/HRP20180080T1/hr unknown
- 2014-12-19 LT LTEP14815843.9T patent/LT3083625T/lt unknown
- 2014-12-19 NO NO14815843A patent/NO3083625T3/no unknown
- 2014-12-19 RU RU2016123363A patent/RU2691105C1/ru active
- 2014-12-19 KR KR1020167019551A patent/KR102405462B1/ko active Active
- 2014-12-19 BR BR112016014151-2A patent/BR112016014151B1/pt active IP Right Grant
- 2014-12-19 CA CA2933755A patent/CA2933755C/en active Active
-
2016
- 2016-05-17 IL IL245672A patent/IL245672B/en unknown
- 2016-05-17 ZA ZA2016/03337A patent/ZA201603337B/en unknown
-
2018
- 2018-01-15 CY CY20181100041T patent/CY1120035T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6437559B2 (ja) | Ｗｅｅ−１キナーゼ阻害剤として有用なピリミドピリミジノン | |
| JP7073359B2 (ja) | ユビキチン特異的プロテアーゼ７の阻害剤としてのピペリジン誘導体 | |
| US10766902B2 (en) | Wee-1 inhibiting pyrazolopyrimidinone compounds | |
| CN102548557B (zh) | 用于降低β-淀粉状蛋白生成的化合物 | |
| TWI624467B (zh) | 選擇性經取代之喹啉化合物 | |
| CN104470925A (zh) | 作为激酶抑制剂的咪唑并三嗪甲腈 | |
| EP3166608A1 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| WO2024153155A1 (zh) | 双杂环wrn抑制剂、其制备方法及其应用 | |
| JP7760622B2 (ja) | 皮膚病変の治療 | |
| WO2019125798A1 (en) | Carbamate and urea compounds as multikinase inhibitors | |
| CN111747954B (zh) | 吡嗪化合物和其用途 | |
| HK1227877B (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| HK1227877A1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| HK40037929B (en) | Pyrazine compounds and uses thereof | |
| HK40037929A (en) | Pyrazine compounds and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20161102 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20161102 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170919 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180627 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180703 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180927 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181023 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181114 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6437559 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |